| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
7,862 |
6,705 |
$215K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,768 |
4,060 |
$203K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
9,754 |
3,590 |
$168K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,838 |
2,548 |
$135K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
1,591 |
1,530 |
$99K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,490 |
1,343 |
$87K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
6,896 |
2,460 |
$86K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
5,624 |
2,161 |
$82K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
3,980 |
1,565 |
$63K |
| 20610 |
|
479 |
331 |
$13K |
| 95886 |
|
148 |
133 |
$6K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
828 |
658 |
$4K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
489 |
465 |
$3K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
344 |
276 |
$2K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
232 |
166 |
$2K |
| 98941 |
Chiropractic manipulative treatment; spinal, 3-4 regions |
120 |
72 |
$2K |
| 20611 |
|
43 |
39 |
$2K |
| 73630 |
|
105 |
88 |
$2K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
40 |
33 |
$2K |
| 99243 |
|
27 |
27 |
$1K |
| 97161 |
|
12 |
12 |
$871.44 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
130 |
115 |
$696.07 |
| 73564 |
|
34 |
25 |
$633.93 |
| 72110 |
|
25 |
24 |
$618.13 |
| 73610 |
|
43 |
36 |
$552.19 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
18 |
12 |
$352.16 |
| 20552 |
|
25 |
12 |
$305.06 |
| 73140 |
|
13 |
12 |
$166.81 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
198 |
162 |
$127.49 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
28 |
26 |
$2.15 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
24 |
24 |
$0.03 |